RxSight Class Action Lawsuit (RXST)
A shareholder case following a $42.5m guidance cut and a sharp fall in Light Delivery Device sales. If you are a patient rather than an investor, this is not your case.
Active litigation. There is no claim form and no payout yet.
| Company | RxSight, Inc. (NASDAQ: RXST) |
|---|---|
| Case | Makaveev v. RxSight, Inc., No. 25-cv-01596 |
| Court | US District Court, Central District of California |
| Class period | 7 November 2024 – 8 July 2025 |
| Claims | §10(b) and §20(a), Securities Exchange Act of 1934 |
| Lead plaintiff deadline | 22 September 2025 — passed, and it does not affect your recovery |
| Can you file a claim? | Not yet. Realistically 2028–2030 if the case settles. |
Shareholders who lost money on RXST stock — this page.
Patients who had a Light Adjustable Lens implanted and experienced a problem — a separate medical device and personal injury matter with nothing to do with this case. Recovery here goes to investors only.
Who the securities case covers
Anyone who purchased or acquired RxSight securities between 7 November 2024 and 8 July 2025, inclusive.
What happened
RxSight sells the Light Adjustable Lens (LAL) system used in cataract surgery, along with the Light Delivery Device (LDD) — the capital equipment that adjusts the lens after implantation. Its growth model depends on placing LDDs with practices and then driving recurring LAL sales through utilisation of that installed base.
On 8 July 2025 RxSight released preliminary Q2 2025 results showing significant declines in LDD sales, LAL utilisation, and overall revenue, and cut full-year 2025 guidance by approximately $42.5 million at the midpoint. The share price fell sharply.
What the case alleges
The complaint charges RxSight and certain executives with violations of the Securities Exchange Act of 1934, alleging that during the class period they made materially false and misleading statements and failed to disclose adverse facts about the business — with the alleged truth emerging in the 8 July 2025 preliminary results and guidance cut. Allegations only; the company denies wrongdoing and the case has not been tested on a motion to dismiss.
The question this case turns on
The interesting issue is timing rather than existence. A guidance cut of that size, arriving as a preliminary announcement ahead of the scheduled quarterly report, invites the argument that the deterioration was visible internally well before it was disclosed — utilisation and device placement are metrics a company tracks continuously, not quantities discovered at quarter end.
The defence to that is equally standard: adoption curves for elective, premium-priced procedures are genuinely volatile, guidance is forward-looking and protected, and slower-than-hoped uptake is a business disappointment rather than a misstatement. The motion to dismiss is where that gets resolved, and it is the event worth watching.
What to do now
- ✓Preserve your RXST trade confirmations for the November 2024 – July 2025 window, with dates, quantities, and prices per share.
- ✓Do nothing else. Opt-out class — you are already a member if you bought in the period. No lawyer, no retainer, no cost.
- ✓Set an alert rather than tracking the docket.
Frequently Asked Questions
I missed the 22 September 2025 lead plaintiff deadline.
It does not matter for your recovery. That deadline decided only who directs the litigation.
I bought after the 8 July 2025 drop. Am I covered?
No. The class period closes on the corrective disclosure date. Shares bought afterwards were priced with the news already public.
The press releases mention losses over $100,000. I lost less than that.
Those thresholds are law firms filtering for lead plaintiff candidates. Class membership and eventual recovery have no minimum — small holders are paid pro rata in every settlement.
How much might I get?
Nobody can say before a settlement exists. Your share would depend on the size and timing of your class-period purchases relative to the alleged inflation, and on the total fund.
See every settlement you qualify for
Tell SettleScout which brands you use and it matches you with open settlements, estimates your payouts, and reminds you before every deadline.
Free to download. Premium plans available.